ACE-232 for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but you cannot use medications or supplements that affect certain liver enzymes or heart rhythms. There is also a washout period (time without taking certain medications) for anti-cancer drugs or treatments.
How does the drug ACE-232 differ from other prostate cancer treatments?
Are You a Good Fit for This Trial?
This trial is for adults with metastatic castration-resistant prostate cancer. Participants must have a specific type of advanced prostate cancer that has spread and does not respond to hormone therapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1A Dose Escalation
Assess safety, tolerability, pharmacokinetics, and pharmacodynamics to determine the maximum tolerated dose (MTD) of ACE-232
Phase 1B Dose Optimization
Patients with AR gene alterations are treated at two different dose levels to establish the recommended Phase 2 dose (RP2D)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ACE-232
Find a Clinic Near You
Who Is Running the Clinical Trial?
Acerand Therapeutics (Hong Kong) Limited
Lead Sponsor